

Eagle Pharmaceuticals to Present at the William Blair 42nd Annual Growth Stock Conference

May 26, 2022

WOODCLIFF LAKE, N.J., May 26, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle") today announced that Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the William Blair 42nd Annual Growth Stock Conference as follows:

Date:	Thursday, June 9, 2022
Time:	9:40AM ET/8:40AM CT
Webcast:	Click Here

About Eagle Pharmaceuticals, Inc.

Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients' lives. Eagle's commercialized products include vasopressin injection, PEMFEXYTM, RYANODEX[®], BENDEKA[®], BELRAPZO[®], TREAKISYM (Japan), and its oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Additional information is available on Eagle's website at www.eagleus.com.

Investor Relations for Eagle Pharmaceuticals, Inc.:

Lisa M. Wilson In-Site Communications, Inc. T: 212-452-2793 E: <u>wilson@insitecony.com</u>